Literature DB >> 11054042

PCR detects HCV RNA in a plasma pool contaminated by a single preseroconversion donation of genotype 5a.

I Thomas1, T Branckaert, E Mathys, R Vranckx, R Laub.   

Abstract

BACKGROUND AND OBJECTIVES: To determine the prevalence of HCV-RNA-positive plasma pools in Belgium, to validate our PCR method and to increase the safety of the released blood products.
MATERIALS AND METHODS: Plasma pools consisting each of about 5,000 donations from Belgian unpaid volunteer blood donors were analysed by PCR for the presence of HCV RNA. Two different extraction methods were compared and validated.
RESULTS: Two out of 367 plasma pools were found to be HCV RNA positive and were discarded. For one of these two pools, the look-back procedure identified an anti-HCV-negative contaminated donation. The HCV genotype of both the contaminated pool and the donation was 5a, a genotype rare in Europe. The viral load of the preseroconverted donation was 2.9 x 10(7) gEq/ml according to the bDNA method.
CONCLUSION: In the case of plasma derivatives, various important steps are already included to increase safety. Nucleic acid testing of manufacturing plasma pools ensures that viral load in the starting material is as low as possible.

Mesh:

Substances:

Year:  2000        PMID: 11054042     DOI: 10.1159/000031214

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  Three cases of infection with hepatitis C virus genotype 5 among Brazilian hepatitis patients.

Authors:  José Eduardo Levi; Deise Tihe Takaoka; Regina Helena Garrini; Roberta Maria Fachini; Roberto Focaccia; Edgar De Bortholi Santos; Heloisa Pedrosa Mitre; João Silva De Mendonça; Norma De Paula Cavalheiro; Antonio Alci Barone; Silvano Wendel
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

2.  Investigating the origin and spread of hepatitis C virus genotype 5a.

Authors:  Jannick Verbeeck; Piet Maes; Philippe Lemey; Oliver G Pybus; Elke Wollants; Ernie Song; Frederik Nevens; Johan Fevery; Wayne Delport; Schalk Van der Merwe; Marc Van Ranst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.